References
- Amayo AA, Kuria JG (2009). Clinical application of tumour markers: a review. East Afr Med J, 86, 76-83.
- Amino N, Kuro R, Yabu Y, et al (1981). Elevated levels of circulating carcinoembryonic antigen in hypothyroidism. J Clin Endocrinol Metab, 52, 457-62. https://doi.org/10.1210/jcem-52-3-457
- Ballehaninna UK, Chamberlain RS (2011). Serum CA 19-9 as a biomarker for pancreatic cancer-a comprehensive review. Indian J Surg Oncol, 2, 88-100. https://doi.org/10.1007/s13193-011-0042-1
- Bast RC Jr, Badgwell D, LuZ, et al (2005). New tumor markers: CA125 and beyond. Int J Gynecol Cancer, 15, 274-81. https://doi.org/10.1111/j.1525-1438.2005.00441.x
- Cheung K, Graves CR, Robertson JF (2000). Tumor marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev, 26, 91-102. https://doi.org/10.1053/ctrv.1999.0151
- Christoforidis A, Lefkou E, Vlachaki E, et al (2007). Evaluation of serum tumour markers concentrations in patients with homozygous beta-thalassaemia in relation to demographical, clinical and biochemical parameters. Ann Hematol, 86, 837-41. https://doi.org/10.1007/s00277-007-0348-9
- Collazos J, Genolla J, Ruibal A (1992). Preliminary study of alpha-fetoprotein in nonmalignant liver diseases. A clinicobiochemical evaluation. Int J Biol Markers, 7, 97-102.
- Dikensoy E, Balat O, Ugur MG, Ozkur A, Erkilic S (2007). Serum CA-125 is a good predictor of benign disease in patients with postmenopausal ovarian cysts. Eur J Gynaecol Oncol, 28, 45-7.
- Dogan UB, Gumurdulu Y, Golge N, Kara B (2011). Relationship of CA 19-9 with choledocholithiasis and cholangitis. Turk J Gastroenterol, 22, 171-7.
- Duffy MJ (2001). Clinical uses of tumor markers: a clinical review. Crit Rev Clin lab Sci, 38, 225-62. https://doi.org/10.1080/20014091084218
- Escudero JM, Auge JM, Filella X, et al (2011). Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem, 57, 1534-44. https://doi.org/10.1373/clinchem.2010.157073
- Forones NM, Queiroz LA, Ferraz ML, Parise ER (1995). Alphafetoprotein in hepatic tumours and benign liver diseases. Rev Assoc Med Bras, 41, 91-3.
- Goonetilleke KS, Siriwardena AK (2007). Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol, 33, 266-70. https://doi.org/10.1016/j.ejso.2006.10.004
- Harada T, Kubota T, Aso T (2002). Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis. Fertil Steril, 78, 733-9. https://doi.org/10.1016/S0015-0282(02)03328-9
- Howaizi M, Abboura M, Krespine C, et al (2003). A new cause for CA19.9 elevation: heavy tea consumption. Gut, 52, 913-4. https://doi.org/10.1136/gut.52.6.913
- Kannagi R (2007). Carbohydrate antigen sialyl Lewis a-its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J, 30, 189-209.
- Knudsen UB, Tabor A, Mosgaard B, et al (2004). Management of ovarian cysts. Acta Obstet Gynecol Scand, 83, 1012-21. https://doi.org/10.1111/j.0001-6349.2004.00607.x
- Kobeisy MA, Morsy KH, Galal M, et al (2012). Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol, 13, 49-53. https://doi.org/10.1016/j.ajg.2012.06.004
- Krupey J, Wilson T, Freedman SO, Gold P, (1972). The preparation of purified carcinoembryonic antigen of the human digestive system from large quantities of tumor tissue. Immunochemistry, 9, 617-22. https://doi.org/10.1016/0019-2791(72)90247-9
- Lim YK, Kam MH, Eu KW, (2009). Carcinoembryonic antigen screening: how far should we go? Singapore Med J, 50, 862-5.
- Locker GY, Hamilton S, Harris J, et al (2006). ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24, 5313-27. https://doi.org/10.1200/JCO.2006.08.2644
- Malaguarnera G, Giordano M, Paladina I, et al (2010). Serum markers of hepatocellular carcinoma. Dig Dis Sci, 55, 2744-55. https://doi.org/10.1007/s10620-010-1184-7
- Marechal F, Berthiot G, Deltour G (1988). Serum levels of CA-50, CA-19-9, CA-125, CA-15.3, enolase and carcinoembryonic antigen in non neoplastic diseases of the lung. Anticancer Res, 8, 677-80.
- Pavai S, Yap SF (2003). The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia, 58, 667-72.
- Perkins GL, Slater ED, Sanders MD, Prichard JG (2003). Serum tumor markers. Am Fam Physician, 68, 1075-82.
- Ryu JS, Lee HJ, Cho JH, Han HS, Lee HL (2003). The implication of elevated carcinoembryonic antigen level in pleural fluid of patients with non-malignant pleural effusion. Respirology, 8, 487-91. https://doi.org/10.1046/j.1440-1843.2003.00502.x
- Sajid KM, Chaouachi K, Mahmood R (2008). Hookah smoking and cancer: carcinoembryonic antigen (CEA) levels in exclusive/ever hookah smokers. Harm Reduct J, 5, 19. https://doi.org/10.1186/1477-7517-5-19
- Serefhanoglu S, Buyukasik Y, Emmungil H, et al (2010). Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia. Int J Med Sci, 8, 30-8.
- Shiota Y, Furuya K, Kitade M, Ueda N, (1989). CEA and CA19-9 in BALF from patients with idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi, 27, 887-93.
- Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D, et al (2004). Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology, 67, 359-67. https://doi.org/10.1159/000082919
- Symeonidis A, Kouraklis-Symeonidis A, Constantinidou I, et al (2006). Increased CA-15.3 levels in the serum of patients with homozygous beta-thalassaemia and sickle cell/betathalassaemia. Br J Haematol, 133, 692-4. https://doi.org/10.1111/j.1365-2141.2006.06121.x
- Szubert M, Suzin J, Wierzbowski T, Kowalczyk-Amico K (2012). CA-125 concentration in serum and peritoneal fluid in patients with endometriosis -preliminary results. Arch Med Sci, 8, 504-8.
- Topatan B, Basaran A, (2011). CA-125 and heart failure: reiteration and reappraisal. Int J Cardiol, 153, 76-8. https://doi.org/10.1016/j.ijcard.2011.08.054
- Topolcan O, Holubec L, Polivkova V, et al (2007). Tumor markers in pleural effusions. Anticancer Res, 27, 1921-4.
- Triantafillidis JK, Cheracakis P, Konstantellou E, Hyphantis T, (2002). Increased serum levels of the tumor marker CA 15-3 on patients with pernicious (Biermer) anemia. Oncology, 63, 306-7. https://doi.org/10.1159/000065495
- Wagner IC, Guimaraes MJ, da Silva LK, de Melo FM, Muniz MT (2007). Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15-3 in patients with pleural effusion. J Bras Pneumol, 33, 185-91. https://doi.org/10.1590/S1806-37132007000200013
- Witherspoon LR, Shuler SE, Alyea K, Husserl FE (1983). Carcinoembryonic antigen: assay following heat compared with perchloric acid extraction in patients with colon cancer, non-neoplastic gastrointestinal diseases, or chronic renal failure. J Nucl Med, 24, 916-21.
- Xiaofang Y, Yue Z, Xialian X, Zhibin Y (2007). Serum tumour markers in patients with chronic kidney disease. Scand J Clin Lab Invest, 67, 661-7. https://doi.org/10.1080/00365510701282326
- Yu H, Li R, Zhang L, et al (2012). Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients. Exp Diabetes Res, 2012, 745189.
- Yue T, Maupin KA, Fallon B, et al (2011). Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One, 6, 29180. https://doi.org/10.1371/journal.pone.0029180